UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 146

Sortiert nach

Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab

Digestive diseases and sciences, 2009-11, Vol.54 (11), p.2538-2540

2009

Volltextzugriff (PDF)

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

European journal of cancer (1990), 2015-09, Vol.51, p.S106-S107

2015

Volltextzugriff (PDF)

Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006

EUROPEAN JOURNAL OF CANCER, 2017, Vol.72, p.S122-S123

2017

Volltextzugriff (PDF)

3335 Intralesional administration of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma induces durable tumor responses

European journal of cancer (1990), 2015-09, Vol.51, p.S676-S677

2015

Volltextzugriff (PDF)

1132P Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy

Annals of oncology, 2023-10, Vol.34, p.S679-S679

2023

Volltextzugriff (PDF)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

The New England journal of medicine, 2017-11, Vol.377 (19), p.1824-1835

2017

Volltextzugriff (PDF)

An Acquired Factor VIII Inhibitor in a Patient with HIV and HCV: A Case Presentation and Literature Review

Case reports in hematology, 2013-01, Vol.2013, p.628513-7

2013

Volltextzugriff (PDF)

Treatment of taste alterations in chemotherapy patients using the “miracle fruit”: Preliminary analysis of a pilot study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e19523-e19523

2010

Volltextzugriff (PDF)

Intracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

Annals of oncology, 2019-10, Vol.30, p.v555

2019

Volltextzugriff (PDF)

1360P - Intracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

Annals of oncology, 2019-10, Vol.30, p.v555-v555

2019

Volltextzugriff (PDF)

1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]

Annals of oncology, 2021-09, Vol.32, p.S904-S904

2021

Volltextzugriff (PDF)

Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease

Cancer management and research, 2015-01, Vol.7 (default), p.47-50

2015

Volltextzugriff (PDF)

371 Phase 2 randomized discontinuation trial (RDT) of XL184 in patients (pts) with advanced solid tumors

European journal of cancer supplements, 2010, Vol.8 (7), p.117-117

2010

Volltextzugriff (PDF)

1141 - Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006

European journal of cancer (1990), 2017-02, Vol.72, p.S122-S123

2017

Volltextzugriff (PDF)

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

Annals of oncology, 2016-10, Vol.27, p.vi393-vi393

2016

Volltextzugriff (PDF)

Calm Study: Secondary Endpoints of a Phase Ii Study of a Novel Oncolytic Immunotherapeutic Agent, Coxsackievirus A21, Delivered Intratumorally in Patients with Advanced Malignant Melanoma

Annals of oncology, 2014-09, Vol.25, p.iv382

2014

Volltextzugriff (PDF)

Phase 1 Study Evaluating Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death Ligand-1 (Pd-L1) Antibody, in Combination with Dabrafenib and Trametinib or Trametinib Alone in Patients with Unresectable or Metastatic Melanoma

Annals of oncology, 2014-09, Vol.25, p.iv392

2014

Volltextzugriff (PDF)

Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8560-8560

2010

Volltextzugriff (PDF)

Phase Ii Study of Nilotinib in Melanoma Harboring Kit Alterations Following Progression or Intolerance to Prior Kit Inhibition

Annals of oncology, 2014-09, Vol.25, p.iv385

2014

Volltextzugriff (PDF)

Clinical and Immune Responses in Advanced Melanoma Patients Immunized With an Anti-Idiotype Antibody Mimicking Disialoganglioside GD2

Journal of clinical oncology, 2000-01, Vol.18 (2), p.376-384

2000

Volltextzugriff (PDF)

A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma

Journal of immunotherapy, 2009-01, Vol.32 (1), p.79-85

2009

Volltextzugriff (PDF)

A phase II trial of oxaliplatin in patients with advanced melanoma

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.18016-18016

2006

Volltextzugriff (PDF)

Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells

Leukemia, 1988-12, Vol.2 (12), p.810-813

1988

Volltextzugriff (PDF)

Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells

Cancer research (Baltimore), 1989-08, Vol.49 (15), p.4120-4125

1989

Volltextzugriff (PDF)

1360PIntracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1 – 25 von 146

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(141)
Mit Volltextzugriff
(135)

Publikationsform

Artikel
(143)
Buchkapitel
(3)

Sprache

Englisch
(146)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006

3335 Intralesional administration of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma induces durable tumor responses

1132P Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

An Acquired Factor VIII Inhibitor in a Patient with HIV and HCV: A Case Presentation and Literature Review

Treatment of taste alterations in chemotherapy patients using the “miracle fruit”: Preliminary analysis of a pilot study

Intracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

1360P - Intracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]

Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease

371 Phase 2 randomized discontinuation trial (RDT) of XL184 in patients (pts) with advanced solid tumors

1141 - Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

Calm Study: Secondary Endpoints of a Phase Ii Study of a Novel Oncolytic Immunotherapeutic Agent, Coxsackievirus A21, Delivered Intratumorally in Patients with Advanced Malignant Melanoma

Phase 1 Study Evaluating Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death Ligand-1 (Pd-L1) Antibody, in Combination with Dabrafenib and Trametinib or Trametinib Alone in Patients with Unresectable or Metastatic Melanoma

Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma

Phase Ii Study of Nilotinib in Melanoma Harboring Kit Alterations Following Progression or Intolerance to Prior Kit Inhibition

Clinical and Immune Responses in Advanced Melanoma Patients Immunized With an Anti-Idiotype Antibody Mimicking Disialoganglioside GD2

A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma

A phase II trial of oxaliplatin in patients with advanced melanoma

Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells

Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells

1360PIntracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

Suchergebnisse filtern